Journal: PLOS One

Article Title: Alaska pollock protein as a functional dietary source for promoting skeletal muscle hypertrophy and lipid metabolic remodeling

doi: 10.1371/journal.pone.0348366

Figure Lengend Snippet: Immunofluorescence staining of the superficial region of the gastrocnemius muscle at (a) 90 and (b) 210 min post-feeding. Black indicates MyHC IIx–positive fibers, and green indicates MyHC IIb–positive fibers. The cross-sectional area of each fiber was calculated, and data are presented as the mean ± SEM. Statistical comparisons were performed using Student’s t -test (90 min: N = 3; 210 min: N = 4). *; p < 0.05, **; p < 0.01. Scale bar = 100 μm.

Article Snippet: Sections were fixed with acetone and incubated overnight at 4°C with primary antibodies against MyHC IIa (SC-71) and MyHC IIb (BF-F3), obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA, USA).

Techniques: Immunofluorescence, Staining

Journal: bioRxiv

Article Title: Metal-induced energy transfer uncovers activation-induced axial reorganization of signaling complexes inside cells

doi: 10.64898/2026.04.23.719849

Figure Lengend Snippet: (A) Cell surface GP130 is dimerized by its agonist IL-6, which is presented via the co-receptor IL-6Rα. GP130 dimerization activates JAK1, associated with GP130 via its FERM-SH2 (FS) domain, by enabling interactions between the regulatory pseudokinase (PK) domains that promote cross-phosphorylation of the tyrosine kinase (TK) domains. Activated JAK1 subsequently phosphorylates several Tyr residues in the C-terminal IDR of GP130 (pTyr, orange). JAK1 activity can be blocked by the inhibitor Ruxolitinib (Ruxo). (B) Strategy for MIET-based axial distance mapping of the GP130 ICD. GP130, with its ECD replaced by an ALFA nanobody, is captured into ALFA-tag functionalized nanodots, positioning the ICD at a well-defined distance from the gold surface. Fluorophores at defined positions along the ICD (ii-iv) report axial distances via MIET-dependent fluorescence lifetime quenching. (C) Fabrication of ALFA-functionalized bNDAs on MIET substrates in two steps: Capillary nanostamping of PLL-ALFA onto a VTMS-silanized MIET substrate coated with a silica spacer (I), followed by backfilling with PLL-PEG-RGD (II).

Article Snippet: NDAs were functionalized with 200 nM mEGFP-ALFAnb in HBS for 15 min, washed five times with HBS, and incubated overnight at 4°C with 20 nM anti-GFP nanobody conjugated to docking strand F3 (Massive Photonics).

Techniques: Phospho-proteomics, Activity Assay, Fluorescence

Journal: bioRxiv

Article Title: Aspirin hastens resolution of skeletal muscle inflammation and promotes recovery of muscle strength following acute injury

doi: 10.64898/2026.04.21.719989

Figure Lengend Snippet: A: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes that were treated during differentiation with various NSAIDs, including aspirin (ASA), indomethacin (INDO), ibuprofen (IBU), celecoxib, and SC-236 at the indicated concentrations. Cells were stained for myosin heavy chain (MyHC, green), myogenin (MyoG, red), and DAPI (nuclei, blue). B: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes treated with doses of INDO ranging from 6.25 µM to 400 µM. C-E : Quantitative analysis of INDO-treated cells showing a dose-dependent decrease in DAPI + cell density ( C ), differentiation index (%) ( D ), and myotube area (%) ( E ). F: Representative images of ASA-treated myotubes ranging from 62.5 µM to 4 mM. H–J: Quantification of DAPI + cell density ( H ), differentiation index (%) ( I ), and myotube area (%) ( J ) in C2C12 cells receiving ASA treatment. K: Representative images comparing the effects of ASA (2 mM), INDO (200 µM), and the combination of INDO + ASA on C2C12 myotube morphology. L-N: Statistical comparison of cell density ( L ), differentiation index (%) ( M ), and myotube area (%) ( N ) across vehicle and treatment groups. Data are expressed as mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Holm-Šídák post hoc tests. *, **, ***, and **** denotes p<0.05, p<0.01, p<0.001, and p<0.0001 between indicated groups, respectively. # denotes p<0.05 difference between ASA and vehicle groups.

Article Snippet: Primary antibodies used include MyHC type I [Developmental Studies Hybridoma Bank (DSHB), BA-D5c, 1:100], MyHC type IIA (DSHB, SC-71c, 1:100), MyHC type IIB (DSHB, BF-F3c, 1:100), eMHC (DSHB, F1.652s, 1:20), Ly6G (GR1) (Bio-Rad, MCA2387, 1:50), CD68 (Bio-Rad, MCA1957, 1:200), CD206 (Bio-Rad, MCA2387, 1:50), and laminin (Abcam, ab7463, 1:200).

Techniques: Immunofluorescence, Staining, Comparison